UK 356618
UK 356618 性质
| 熔点 | 93-102oC |
|---|---|
| 密度 | 1.124±0.06 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | 二甲基亚砜：≥25mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 9.16±0.20(Predicted) |
| 颜色 | 白色至棕褐色 |
| 旋光度 (Optical Rotation) | [α]/D >+25.0°, c = 0.5 in methanol |
| InChIKey | JJHRUUKMPWUYIB-HVOSOHGQSA-N |
| SMILES | C[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCc1ccc(c(C)c1)-c2ccccc2)CC(=O)NO)C(C)(C)C)c3ccccc3 |
UK 356618 用途与合成方法
|
MMP-3 5.9 nM (IC 50 ) |
MMP-13 73 nM (IC 50 ) |
MMP-9 0.84 μM (IC 50 ) |
MMP-2 1.79 μM (IC 50 ) |
MMP-14 1.9 μM (IC 50 ) |
MMP-1 51 μM (IC 50 ) |
Inhibition of MMP-3 and selectivity over MMP-2 was remarkably sensitive to the size of the substituent and is clearly optimal for a methyl group (UK 356618, compound 4j). UK 356618 is more widely profiled against other MMPs.
MMP-13 is closely involved in IL-6 or TNF-α increasing tumor metastasis. MMP-13 deficiency abrogate TNF-α effect on lung cancer cell migration. UK 356618 treatment efficiently abolished the effect of TNF-α on cell migration in NCI-H446 cells.
UK 356618 (15 mg/kg; intravenous injection; for 24 h or 7 days; male Wistar rats) treatment at reperfusion significantly reduces MMP3 activity in the brain.
| Animal Model: | Hyperglycemic male Wistar rats injected with middle cerebral artery occlusion (MCAO) |
| Dosage: | 15 mg/kg |
| Administration: | Intravenous injection; for 24 h or 7 days |
| Result: | Significantly reduced MMP3 activity in the brain. |
UK 356618 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-107394 | UK 356618 | 230961-08-7 | 1mg | 3094 |
| 2025-12-22 | HY-107394 | 230961-08-7 | 10 mM * 1 mLin DMSO | 9491 |
